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Objectives: Although carbapenem susceptibility testing has been recommended for all Enterobacteriaceae from
clinical specimens, for practical reasons a carbapenem is not included in many primary antibiotic panels for urine
specimens. The ‘iCREST’ study sought carbapenemase-producing Enterobacteriaceae (CPE) in routine urine
specimens yielding Gram-negative growth in five diagnostic laboratories in the UK. We sought also to compare
locally and centrally determined MICs of meropenem and ceftazidime/avibactam.
Methods: Positive growth from up to 2000 urine specimens per laboratory was plated onto chromIDV
R
CARBA
SMART agar. Suspected CPE colonies were tested locally by Etest for susceptibility to meropenem and ceftazi-
dime/avibactam, and referred to central laboratories for PCR confirmation of CPE status and microbroth MIC
determination.
Results: Twenty-two suspected CPE were identified from 7504 urine specimens. Ten were confirmed by PCR to
have NDM (5), IMP (2), KPC (2) or OXA-48-like (1) carbapenemases. Locally determined ceftazidime/avibactam
MICs showed complete categorical agreement with those determined centrally by microbroth methodology.
The seven ceftazidime/avibactam-resistant isolates (MICs256 mg/L) had NDM or IMP metallo-carbapenemases.
Conclusions: The frequency of confirmed CPE among Gram-negative urinary isolates was low, at 0.13%
(10/7504), but CPE were found in urines at all five participating sites and the diversity of carbapenemase genes
detected reflected the complex epidemiology of CPE in the UK. These data can inform local policies about the
cost-effectiveness and clinical value of testing Gram-negative bacteria from urine specimens routinely against a
carbapenem as part of patient management and/or infection prevention and control strategies.
Introduction
Enterobacteriaceae are a common cause of community- and
hospital-acquired urinary tract infections, and have become
increasingly multiresistant to first- and second-line antibiotics.1
Carbapenems are used to treat patients with severe life-
threatening infections caused by MDR Enterobacteriaceae, includ-
ing those with ESBLs.1 The rapid global increase in carbapenem
resistance due to carbapenemase-producing Enterobacteriaceae
(CPE) has become a public health crisis, threatening delivery of
healthcare and patient safety.2
In 2013–14, the European Survey on Carbapenemase-
Producing Enterobacteriaceae (EuSCAPE) investigated the inci-
dence of CPE among carbapenem-non-susceptible isolates of
Klebsiella pneumoniae and Escherichia coli from 36 European
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countries.3 As part of this survey, 32 CPE isolates were confirmed
from among 102 suspected non-susceptible K. pneumoniae and
E. coli submitted from 21 sentinel UK laboratories. The period prev-
alence of CPE in participating UK laboratories was 0.02%, and pro-
ducers of KPC, OXA-48-like, NDM and VIM carbapenemases were
detected, indicating a continuing diverse epidemiology in the UK.4
To improve rapid detection of CPE, it has been suggested that
all Enterobacteriaceae from clinically significant specimens should
ideally be tested against a carbapenem.5 However, for practical
reasons, a carbapenem is not included in many primary antibiotic
panels for urine specimens; many diagnostic laboratories have
local algorithms and test a carbapenem only against isolates
found resistant to primarily tested b-lactams, such as co-
amoxiclav.6 The infection-Carbapenem Resistance Evaluation
Surveillance Trial (iCREST) is an in vitro sentinel surveillance pro-
gramme, which aimed, therefore: (i) to investigate the potential
for under-detecting CPE in urine specimens collected in five
European countries with differing CPE epidemiologies,3 specifically
France, Germany, Italy, Spain and the UK; and (ii) to determine the
susceptibility of urinary CPE to ceftazidime/avibactam, a new ceph-
alosporin/b-lactamase inhibitor combination with in vitro activity
that includes many MDR Enterobacteriaceae,2,7 and comparator
antibiotics. Here we present the results from the iCREST-UK study.
Materials and methods
Participating laboratories
Five diagnostic laboratories in London (four) and Birmingham (one) partici-
pated in the iCREST-UK study. Prior to this survey, all had identified CPE occur-
ring sporadically, but none was considered to have an endemic problem with
these organisms. Only one of the participating laboratories routinely tested
urinary Gram-negative isolates for resistance to carbapenems in its primary
antibiotic panels. For iCREST-UK, each laboratory was required to screen up to
2000 consecutive positive urine specimens for suspected CPE.
Local CPE screening and susceptibility testing
Primary plating of urine specimens collected from inpatients and outpa-
tients was performed according to each participating laboratory’s routine
practices. The laboratories sought CPE from urine specimens that were posi-
tive for Gram-negative bacteria, including those that yielded mixed growth.
Growth from the medium specified in each laboratory’s relevant Standard
Operating Procedures (SOPs) was suspended in saline, calibrated to a
0.5 McFarland standard to reach an inoculum of 105 cfu/mL, and then cul-
tured on chromIDV
R
CARBA SMART agar (bioMérieux, Marcy-l’Étoile, France)
and incubated aerobically at 35+2 C for 18–24 h, in accordance with the
manufacturer’s instructions. Quality control strains K. pneumoniae ATCCV
R
BAA-1705TM (which produces a KPC carbapenemase) and K. pneumoniae
ATCCV
R
700603TM (which produces SHV-18 ESBL, but is carbapenemase
negative) were used in each participating laboratory.
Colonies considered indicative for CPE showed the following characteris-
tic colours, according to the manufacturer, on chromIDV
R
CARBA SMART
agar: E. coli, pink to burgundy colonies or translucent colonies with a pink to
burgundy centre; and Klebsiella spp., Enterobacter spp., Serratia spp. and
Citrobacter spp., bluish-green to bluish-grey colonies. Identification was
determined according to each participating laboratory’s routine practices.
One suspected CPE colony of each of these colours (where possible) was
subcultured from each specimen yielding growth on this selective medium.
Colonies growing on chromIDV
R
CARBA SMART agar but identified (by char-
acteristic colour) as non-Enterobacteriaceae were discarded and were not
studied further.
The selected colonies of suspected CPE were tested locally for suscepti-
bility to both meropenem and ceftazidime/avibactam using Etest
(bioMérieux) according to the manufacturer’s instructions and were sub-
mitted for further centralized testing.
Centralized confirmation and characterization of CPE
On receipt in the two central reference laboratories (PHE’s Birmingham lab-
oratory and the PHE AMRHAI Reference Unit), the species identification of
all suspected CPE was confirmed by MALDI-TOF MS (Bruker Daltonik GmbH,
Bremen, Germany), and genes encoding KPC, NDM, OXA-48-like and VIM
carbapenemases were sought by PCR according to the EuSCAPE project
protocols.3,4 Two PCR-negative isolates were later screened for other
metallo-carbapenemase genes,8 because their presence was suggested by
microbroth susceptibility results.
Isolates were tested for susceptibility to a range of antibiotics, including
imipenem, meropenem, ceftazidime, ceftazidime/avibactam, aztreonam,
amikacin, colistin, levofloxacin and tigecycline, using a broth microdilution
method (SensititreV
R
, TREK Diagnostic Systems, Cleveland, OH, USA). MICs
were interpreted using EUCAST v. 7.1 breakpoints.9
Data capture and ethics consideration
All participating diagnostic laboratories and the central reference laborato-
ries entered their anonymized study data into a centralized electronic data-
base (Micron Research Ltd, Ely, UK), including: patient’s age range (,18, 18–
65 and .65 years); patient’s gender; isolate identification; locally deter-
mined Etest MICs of ceftazidime/avibactam and meropenem; centrally
determined broth microdilution MICs; and any carbapenemase gene
detected.
The iCREST-UK study protocol was submitted to PHE’s Research and
Development Office and was determined to be a surveillance study, not
research, and therefore did not require ethical approval. This decision was
communicated and agreed with all participating laboratories.
Results and discussion
Isolation of suspected CPE from urines
Between September 2016 and January 2017, a total of 7504 con-
secutive Gram-negative urinary isolates were cultured on chromIDV
R
CARBA SMART agar plates in the five participating UK diagnostic labo-
ratories. Of these, 22 (0.3%) yielded appropriately coloured colonies
that were suspected to be CPE: E. coli (31.8%, 7/22), K. pneumoniae
(27.3%, 6/22), Enterobacter cloacae (22.7%, 5/22) and one isolate
each of Citrobacter freundii, Enterobacter aerogenes, Morganella
morganii and Serratia marcescens. Participating diagnostic laborato-
ries did not observe non-CPE growth on the selective agar plates.
Furthermore, the local SOPs and algorithms in each participating lab-
oratory also identified these isolates as suspect CPE, so none would
have been missed without participation in the iCREST study.
Of the patients with suspected CPE in urine specimens, 64%
(14/22) were female, 50% (11/22) were aged .65 years, 46%
(10/22) were aged 18–65 years and 4% (1/22) were aged ,18 years.
Locally determined antibiotic susceptibilities
Despite growth on chromIDV
R
CARBA SMART agar, locally per-
formed Etests indicated that most (19/22; 86.4%) suspected CPE
were susceptible to meropenem using EUCAST breakpoints (MIC
range for all suspected CPE, 0.008 to32 mg/L; MIC50, 0.5 mg/L;
MIC90, 8 mg/L); the exceptions were single isolates of E. coli
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meropenem resistance (MICs 4–8 mg/L), and one K. pneumoniae
that was fully resistant (MIC,32 mg/L). However, the merope-
nem MICs for 14/22 (63.6%) suspected isolates were .0.12 mg/L,
which is the screening criterion recommended by EUCAST to iden-
tify suspected CPE.10
Similarly, most (15/22; 68.2%) suspected CPE isolates were found
susceptible to ceftazidime/avibactam by locally performed Etest
(MIC range, 0.016 to .256 mg/L; MIC50, 1 mg/L; MIC90, .256 mg/L).
The exceptions were two isolates of E. coli, three K. pneumoniae, one
E. cloacae and one C. freundii, all with MICs256 mg/L.
Reference centre characterization of suspected CPE
Twenty-one of the 22 suspected CPE isolates were submitted to
the central reference laboratories for confirmatory testing; one
E. coli isolate was lost to follow-up. Of these, eight (36.4%) were
confirmed to be carbapenemase producers in the initial PCR, with
two further isolates confirmed as CPE in expanded PCR screening
(Table 1). Hence the overall rate of confirmed CPE among Gram-
negative urinary isolates from the five participating UK laboratories
was 0.13% (10/7504). None of the patients identified with CPE in
this study was known to the participating laboratories to have
been infected or colonized by CPE previously.
Carbapenemase genes (5 NDM, 2 IMP, 2 KPC and 1 OXA-48-like)
were detected in isolates of four species (Table 1): K. pneumoniae
(n"3), E. coli (n"3), E. cloacae (n"3) and C. freundii (n"1).
Ceftazidime/avibactam MICs: Etest versus microbroth
dilution
Locally determined susceptibilities of ceftazidime/avibactam
(Etest) showed excellent categorical agreement with those deter-
mined centrally by microbroth dilution (Table 2). Seven isolates
found resistant by Etest (MICs256 mg/L) were all confirmed as
such by microbroth dilution (MICs .32 mg/L). Similarly, 14 isolates
reported susceptible to ceftazidime/avibactam by Etest were all
confirmed susceptible by microbroth dilution; MICs determined
by the two methods for most (10/14) susceptible isolates were
identical (eight isolates) or differed 2-fold (two isolates) and were
4–16-fold lower by Etest for the remainder.
There was poorer categorical agreement for meropenem, with
only one of six isolates found resistant by microbroth dilution also
found resistant by Etest in the diagnostic laboratory; two were
reported intermediate and three as susceptible to meropenem
(Table 2).
The seven ceftazidime/avibactam-resistant isolates included
the five NDM producers, as expected because avibactam does
not inhibit metallo-carbapenemases. However, single isolates of
E. cloacae and K. pneumoniae were found to be highly resistant to
both unprotected ceftazidime (MICs .64 mg/L) and ceftazidime/
avibactam (MICs .32 mg/L), but negative by PCR for genes encod-
ing KPC, NDM, OXA-48-like and VIM enzymes. Neither of these two
isolates was resistant to aztreonam (MICs of 4 mg/L, intermediate,
Table 1. In vitro activity of ceftazidime/avibactam and comparators against confirmed CPE (n"10) and non-CPE (n"11)a from urines
Species Carbapenemaseb
MIC (mg/L)
IPM MEM CAZ CAZ/AVI ATM AMK CST LVX TGC
E. cloacae IMP 2 4 .64 .32 4 2 1 0.06 0.5
K. pneumoniae IMP 4 .8 .64 .32 0.12 2 1 0.12 0.5
E. cloacae KPC 8 4 32 0.5 .64 1 1 0.5 1
E. cloacae KPC .8 .8 .64 1 .64 1 0.5 1 1
C. freundii NDM .8 .8 .64 .32 .64 .64 1 8 2
E. coli NDM 4 8 .64 .32 0.25 2 1 .8 0.5
E. coli NDM 8 .8 .64 .32 .64 .64 1 .8 0.5
K. pneumoniae NDM .8 .8 .64 .32 .64 .64 0.5 .8 .2
K. pneumoniae NDM .8 .8 .64 .32 .64 .64 0.5 .8 1
E. coli OXA-48-like 1 2 .64 4 .64 4 0.5 .8 0.5
E. aerogenes none detected 2 0.25 64 2 16 2 1 .8 1
E. cloacae none detected 0.5 0.12 64 1 4 1 0.5 8 4
E. cloacae none detected 4 0.12 4 1 1 1 0.5 0.25 2
E. coli none detected 0.12 0.03 0.12 0.12 0.06 4 0.5 0.06 0.5
E. coli none detected 2 0.25 8 0.12 32 8 1 2 0.5
E. coli none detected 2 0.25 .64 1 .64 4 1 .8 0.5
K. pneumoniae none detected 1 0.12 32 0.25 8 2 1 1 0.5
K. pneumoniae none detected 0.25 0.03 0.25 0.12 0.06 1 0.5 0.06 1
K. pneumoniae none detected 4 2 .64 1 64 .64 0.5 .8 2
M. morganii none detected 4 0.12 1 0.5 0.25 2 .8 0.06 1
S. marcescens none detected 4 0.25 0.5 0.5 0.5 8 .8 0.12 1
IPM, imipenem; MEM, meropenem; CAZ, ceftazidime; CAZ/AVI, ceftazidime/avibactam; ATM, aztreonam; AMK, amikacin; CST, colistin; LVX, levofloxa-
cin; TGC, tigecycline.
aOne suspected CPE isolate was not available for central MIC determination.
bThe iCREST protocol required PCR screening only for KPC, NDM, OXA-48-like and VIM genes. IMP genes were detected in two isolates after expanded
PCR screening, as indicated by their antibiograms.
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and 0.12 mg/L, susceptible; Table 1), which suggested metallo-
carbapenemase activity, and IMP genes were detected in
expanded PCR screening.
Considering other antibiotics, many of the suspected CPE were
confirmed to be MDR (Table 1). Only colistin remained active
against all suspected CPE (MICs 0.5–1 mg/L), when excluding the
single isolates of M. morganii and S. marcescens, both with intrinsic
resistance.
In conclusion, the iCREST-UK study found that the rate of con-
firmed CPE among Gram-negative urinary isolates in the participating
UK laboratories was 0.13%. This rate was substantially lower than
that observed in some other European countries participating in the
iCREST trial, such as Spain.11 The number of positive UK specimens
was very low, but higher than the rate reported in the 2013–14
EuSCAPE survey.3 It should be noted that CPE were found in urines at
all five participating sites and that the diversity of carbapenemase
genes observed (IMP, KPC, NDM and OXA-48-like) reflected the com-
plex epidemiology of CPE in the UK. The proportion of centrally con-
firmed versus suspected CPE (10/22, 45%) was higher in this study
than was reported in the previous EuSCAPE-UK survey (32/102;
31%),4 although this may be explained in part because the EuSCAPE
study did not seek to detect IMP producers and was limited only to
E. coli and K. pneumoniae. More generally, the reported rates of CPE
from urine vary between studies and direct comparison is con-
founded by differences in their geographical setting, the patient pop-
ulations sampled and the laboratory methods used.12–14
Ceftazidime/avibactam was the only agent active against all
isolates with KPC or OXA-48-like carbapenemases but, as
expected, had no activity against the NDM or IMP producers; only
colistin was active against all confirmed CPE in vitro. Furthermore,
although the sample was small, MICs of ceftazidime/avibactam
determined locally showed excellent categorical agreement with
those determined centrally by microbroth dilution; this concord-
ance must be further investigated against larger panels of isolates
and should also consider the accuracy of susceptibilities deter-
mined locally by disc diffusion.
This study identified a currently low prevalence of CPE among
routinely tested urinary specimens from UK hospital and commun-
ity settings, but there is potential for under-diagnosis if laboratories
do not test a carbapenem (meropenem is recommended by
EUCAST10) in their primary or secondary antibiotic panels. These
data can inform local policies and decisions about the cost-
effectiveness and clinical value of routinely testing Gram-negative
bacteria from these specimens as part of patient management
and/or infection prevention and control strategies
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